Analysts Conflicted on These Healthcare Names: Elanco Animal Health (ELAN) and Henry Schein (HSIC)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Elanco Animal Health (ELAN – Research Report) and Henry Schein (HSIC – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Elanco Animal Health (ELAN)
In a report released today, Daniel Clark from Leerink Partners reiterated a Buy rating on Elanco Animal Health, with a price target of $30.00. The company’s shares closed last Tuesday at $25.63.
Clark has an average return of
According to TipRanks.com, Clark is ranked #3225 out of 12136 analysts.
Elanco Animal Health has an analyst consensus of Strong Buy, with a price target consensus of $27.60, representing a 14.7% upside. In a report issued on February 16, Bank of America Securities also maintained a Buy rating on the stock with a $28.00 price target.
See the top stocks recommended by analysts >>
Henry Schein (HSIC)
In a report released today, Michael Cherny from Leerink Partners reiterated a Hold rating on Henry Schein, with a price target of $87.00. The company’s shares closed last Tuesday at $83.60.
According to TipRanks.com, Cherny is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Henry Schein with a $88.50 average price target, implying a 5.4% upside from current levels. In a report released yesterday, William Blair also maintained a Hold rating on the stock.
